BofA lowered the firm’s price target on Galapagos to $41 from $44 and keeps a Neutral rating on the shares. The company’s Q4 update contained incremental pipeline updates and “minor setbacks for the company’s CAR-T portfolio,” says the analyst, who lowered the firm’s pipeline revenue forecast as a result.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GLPG:
- Galapagos reports FY23 revenue EUR 543.8M vs EUR 264M last year
- GLPG Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Galapagos completes transfer of Jyseleca business to Alfasigma
- Galapagos enters GMP manufacturing agreement with Thermo Fisher
- Galapagos collaborates with BridGene Biosciences for small molecule drugs
